文献速递精神分裂症与精神病性障碍

精神分裂症患者毒蕈碱M1受体可用性降低:活体正电子发射断层扫描证据

Lower Muscarinic M1 Receptor Availability in Schizophrenia: In Vivo Positron Emission Tomography Evidence.
PubMed 文献 · Biol Psychiatry · 2026-06-12

该研究利用11C-LSN3172176 PET比较16例精神分裂症患者与16例年龄性别匹配健康对照的脑M1受体可用性,发现患者多个皮层和皮层下区域M1可用性显著降低,效应量大,部分患者全脑M1缺陷超过20%。结论提示M1缺陷可能成为治疗靶点和生物标志物。

要点

  • 精神分裂症患者多个脑区M1受体可用性较健康对照显著降低,效应量大。
  • 额叶、颞叶、顶叶、枕叶皮层及尾状核、壳核、海马、杏仁核均受累。
  • 部分患者全脑M1缺陷超过健康对照均值20%以上,提示存在亚组。

核心结论

  • 精神分裂症患者脑内M1受体可用性在多个皮层和皮层下区域显著低于健康对照。
  • 该活体证据与死后研究一致,支持M1作为治疗靶点和潜在生物标志物。

研究设计与样本

  • 病例对照研究,纳入精神分裂症患者16例和年龄性别匹配健康对照16例。
  • 使用11C-LSN3172176 PET和高分辨率研究断层扫描测量M1可用性。
  • 以半卵圆中心为参考区计算分布容积比(DVRCS)并测量分布容积(VT),将灰质分数区域变异作为协变量校正萎缩。

主要发现

  • 额叶DVRCS降低13%;颞叶DVRCS降低15%、VT降低12%;顶叶DVRCS降低14%、VT降低11%;枕叶DVRCS降低16%、VT降低13%。
  • 尾状核DVRCS降低19%、VT降低15%;壳核DVRCS降低19%、VT降低17%;海马DVRCS降低13%;杏仁核DVRCS降低19%、VT降低16%。
  • 亚组患者全脑M1缺陷较大,DVRCS降低44%、VT降低27%(超过健康对照均值20%)。
  • 探索性分析提示M1可用性与部分临床指标存在关联。

临床怎么用

  • M1受体可用性降低可作为精神分裂症毒蕈碱能治疗的潜在靶点和生物标志物。
  • 对全脑M1缺陷超过健康对照均值20%的亚组患者,可考虑进一步评估毒蕈碱能药物疗效。

局限性

  • 样本量较小(患者16例、对照16例),结论需扩大样本验证。
  • 临床关联为探索性分析,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is growing interest in the contributions of brain muscarinic M1 receptors to the neurobiology of schizophrenia (SZ). Postmortem evidence strongly indicates M1 deficits in patients with SZ. Recently, the U.S. Food and Drug Administration approved xanomeline and trospium chloride, which contains the M1/M4 agonist xanomeline, as the first nondopaminergic medication for SZ. The development of the positron emission tomography ligand 11C-LSN3172176 enables in vivo quantification of brain M1 availability in SZ and its relationship to clinical features. METHODS: M1 availability in patients with SZ (n = 16) was compared with age- and sex-matched healthy control (HC) participants (n = 16) using 11C-LSN3172176 and high-resolution research tomography. Distribution volume ratio relative to the centrum semiovale (DVRCS) and distribution volume (VT) were measured. Regional variation in percent gray matter fraction was included as a covariate to account for potential atrophy. RESULTS: Compared with HCs, patients with SZ showed significantly lower M1 availability across several cortical and subcortical regions, with large effect sizes: frontal (DVRCS: -13%), temporal (DVRCS: -15%, VT: -12%), parietal (DVRCS: -14%, VT: -11%), and occipital (DVRCS: -16%, VT: -13%) cortices; caudate (DVRCS: -19%, VT: -15%); putamen (DVRCS: -19%, VT: -17%); hippocampus (DVRCS: -13%); and amygdala (DVRCS: -19%, VT: -16%). A subgroup of patients (DVRCS: 44%, VT: 27%) showed larger whole-brain M1 deficits (>20% from the mean of HCs). Exploratory analyses suggested associations between M1 availability and selected clinical measures. CONCLUSIONS: Together with postmortem data, these in vivo findings warrant further characterization of M1 deficits in SZ and highlight M1 as a therapeutic target and potential biomarker for muscarinic-based treatments.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Volpi T, Radhakrishnan R, Hird R, et al. Lower Muscarinic M1 Receptor Availability in Schizophrenia: In Vivo Positron Emission Tomography Evidence. Biol Psychiatry. 2026. PMID: 42285196. doi:10.1016/j.biopsych.2026.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。